David A. Boothman
Professor
UT Southwestern Medical Center
USA
Biography
Dr. David A. Boothman is Professor of Pharmacology and Radiation Oncology. Dr. Boothman is a senior leader in the Simmons Comprehensive Cancer Center, serving as Associate Director for Translational Research and co-Director of Experimental Therapeutics. He developed the Laboratory Correlates Group (LCG) and Biomedical Research Core (BRC) infrastructure with Dr. David Gerber. Dr. Boothman works closely with all ET Program themes to promote preclinical and clinical translation. He aids in the development of infrastructure needed for standardized pharmacodynamic (PD) lab correlates. Dr. Boothman also co-leads (with Dr. Jinming Gao) a Cancer Nanomedicine Group within the SCCC. He has been funded by the NIH for the past 27 years, is elective representative for FASEB for the Society of Experimental Biology, and is currently a permanent member of the Radiation Therapy and Biology (RTB) NIH study section. His current research projects include: (a) Use of NQO1 bioactivatable drugs for therapy of human solid NQO1+ cancers; (b) Use of NQO1 bioactivatable drugs to promote the tumor-selective use of DNA repair inhibitors, such as PARP inhibitors; and (c) Elucidating the roles of RNA termination factors for R-loop resolution, DSB repair defects, genetic instability and cancer vulnerabilities. His lab is currently funded by the NIH (2), two grants from the AACR/Pancreatic cancer action network (PanCan) and the Alex Lemonade Society (in collaboration with Drs. Ted Leatsch and James Amatruda).
Research Interest
Dr. David Boothman research interest includes Altered Metabolism in cancer cells, +/-radio- /chemo-therapiesIGF-1 Pathway Regulation, Repair of DNA Double-Strand Breaks and Mismatch lesions, Stress-Inducible and Noncaspase-Mediated Gene Apoptosis, Targeted Cancer Therapeutics, Tumor-specific BER alterations using NQO1 bioactivatable drugs